Figure 11. XOR knockdown ameliorates GEM-mediated antitumor activity.
(A) Differential effect of gemcitabine on the growth of Ctr-miRNA- and XOR-miRNA-transfected RCAS-Neu tumors. Female FVB mice (6-7-wks-old; 6 mice/group) were treated with saline or gemcitabine on day 1, 7, 14 days after intraductal injection of Ctr-miRNA- or XOR-miRNA-transfected cells (5 × 105 cells/mouse). Tumor volumes were calculated and statistically analyzed. The growth of Ctr-miRNA-transfected tumors: saline vs. gemcitabine, p = 0.011; The growth of XOR-miRNA-transfected tumors: saline vs. gemcitabine, p = 0.501; The growth between Ctr-miRNA- and XOR-miRNA-transfected tumors, p = 0.056. (B) Differential effect of gemcitabine on tumor weight. Mice were sacrificed on day 42 after tumor cell injection. Tumors were collected and weighed. The differences in tumor weight between various groups were analyzed by using a Student t test. ** The p value compared to untreated control, < 0.05.